ADAR1 Capital Management, LLC 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 9:04 pm Purchase |
2024-12-31 | 13G | Inhibikase Therapeutics, Inc. IKT |
ADAR1 Capital Management, LLC | 6,994,246 9.990% |
6,994,246 (New Position) |
Filing |